Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

Phase 1 Completed 48 enrolled Boehringer Ingelheim

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days) in healthy male subjects between Japanese and Caucasians

Timeline

Start: 2006-05
Primary completion: 2006-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran	Unknown	110 mg	Oral
Subject	Dabigatran	Unknown	150 mg	Oral

Indications

No indication recorded.